Global Metabolomics Market

CRISPR Technology Market Definition

The CRISPR technology market consists of sales of CRISPR technology products and related services by entities (organizations, sole traders and partnerships) that produce CRISPR technology products and equipment. CRISPR is a genome-editing tool. It is used by researchers/healthcare professionals to alter DNA sequences and modify gene function. CRISPR is also used for correcting genetic defects, treating human diseases, and to yield better crop varieties. CRISPR stands for Clusters Of Regularly Interspaced Short Palindromic Repeats. The CRISPR-Cas9 system consists of two key molecules, — Cas9 and guide RNA, that introduce a change or mutation into the DNA at the desired position. The Cas9 is an enzyme that acts as a pair of ‘molecular scissors’ and can cut the two strands of DNA at a specific location in the genome so that bits of DNA can then be added or removed. The guide RNA (gRNA is a small piece of pre-designed RNA sequence (about 20 bases long) located within a longer RNA scaffold. The scaffold part binds to DNA and the pre-designed sequence ‘guides’ Cas9 to the right part of the genome. This makes sure that the Cas9 enzyme cuts at the right point in the genome. High orthogonality, versatility, and efficiency of CRISPR technology make it a preferred genome editing technology.

Anti-Viral Drug Therapy Market Definition

The anti-viral drug therapy market consists of sales of branded and generic anti-viral drugs and related services by entities (organizations, sole traders and partnerships) that manufacture branded or generic anti-viral drugs to treat microbial infections. The anti-viral drug therapy industry includes establishments that manufacture anti-viral drugs, which are used to treat diseases or illnesses caused by viral infections. Examples of antiviral drugs include idoxuridine, famiciclovir, cidofovir, amantadine, zanamivir, tenofovir, adefovir and ribavirin. Viruses are infective agents comprising of a core of nucleic acids, either RNA or DNA, and are surrounded by a layer of protein. These are not living organisms, and can reproduce only inside a living cell. Anti-viral drugs decrease the ability of viruses to reproduce. These drugs enter the cells infected with virus, and interfere with the ability of the virus to bind to the cell, and stimulate the immune system of the host.

Anti-Viral Drug Therapy Market Definition

The anti-viral drug therapy market consists of sales of branded and generic anti-viral drugs and related services by entities (organizations, sole traders and partnerships) that manufacture branded or generic anti-viral drugs to treat microbial infections. The anti-viral drug therapy industry includes establishments that manufacture anti-viral drugs, which are used to treat diseases or illnesses caused by viral infections. Examples of antiviral drugs include idoxuridine, famiciclovir, cidofovir, amantadine, zanamivir, tenofovir, adefovir and ribavirin. Viruses are infective agents comprising of a core of nucleic acids, either RNA or DNA, and are surrounded by a layer of protein. These are not living organisms, and can reproduce only inside a living cell. Anti-viral drugs decrease the ability of viruses to reproduce. These drugs enter the cells infected with virus, and interfere with the ability of the virus to bind to the cell, and stimulate the immune system of the host.

The laboratory information system market consists of revenue generated by the companies offering laboratory information system software products and related services. A laboratory information system is a software or database that helps in efficient managing of a clinical laboratory for storing, processing, and tracking of data, which used by the hospitals, laboratories, physician offices and clinics for optimizing their workflow. The laboratory information system market covered in this report is segmented by product into standalone LIS, integrated LIS and by end-user into hospital laboratories, independent laboratories, physician office laboratories, others. The global laboratory information system market is expected to grow from $1.59 billion in 2020 to $1.72 billion in 2021 at a compound annual growth rate (CAGR) of 8.2%. The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The laboratory information system market is expected to reach $2.88 billion in 2025 at a CAGR of 14%. The rising demand for lab automation is a major factor driving the growth of the laboratory information system market. A growing number of people are undergoing a series of tests, which in turn, increases the burden on the laboratories. The clinical laboratories are hiring more healthcare personnel to reduce the amount of workload on existing staff and minimize the number of errors associated with it in order to increase the efficiency and efficacy of the lab’s functioning for accurate results. According to the Bureau of Labour Statistics, around 12,000 additional clinical laboratory professionals are required every year to meet the demand, however, only half of the number is entering the field. Thus, laboratories opt for automation to ease the work. For instance, TriCore Reference Laboratories in Albuquerque, Mexico, introduced automation in its 20% of instrumentation, which performs almost 80% of the lab’s samples and displays helping the lab in managing and optimizing its functions for faster and accurate results. High costs associated with implementing and maintenance of laboratory information systems are anticipated to limit the growth of the laboratory information system market. The cost of a laboratory information system ranges from $4,000 and $100,000 and also an additional annual operating cost of $1000 to $5000. The operating costs comprise cost related to the software license, training the healthcare personal, maintenance, and service cost. The laboratories may opt for the lower-cost version owing to the high cost of software even when the requirement is for a higher-cost version to reduce the burden of the laboratories, causing an operational instability. Therefore, the high cost of a laboratory information system is expected to hinder the market. A cloud-based laboratory information system is expected to become the leading trend in the laboratory information systems market. Cloud computing is associated with the sharing of computer resources and services including storage and servers over the internet for a reduced cost, increased speed, productivity, and security of the system in the network. The cloud system in laboratory information systems offers various advantages such as cost-efficiency, better results, and progress without space constrain. For instance, APEX laboratory information system by Apex HealthWare, LLC, Arxspan Laboratory Software? by Bruker Software Solutions, Orchard laboratory information system by Orchard Software Corporation are cloud-based systems, which improve efficiency, reduces errors, and enhance patient care. Thus, a cloud-based laboratory information system is expected to gain significant traction in the laboratory information system market. In October 2019, Francisco Partners, an America-based technology-oriented private equity firm acquired Orchard Software Corporation, a privately-owned company specializing in developing laboratory information systems (LIS), for an undisclosed amount. This acquisition is expected to fuel the innovations and offer new technologies to the orchard customers using the experience of Francisco partners. Orchard Software Corporation was founded in 1993 and is a pioneer in the laboratory information systems, which deploys its software in the physician office, clinics, hospitals, and small laboratories. Major players in the laboratory information system market are Cerner Corporation, McKesson Corporation, Epic Corporation Inc, Medical Information Technology Inc, SCC Soft Computer, Sunquest Information Systems Inc, CompuGroup Medical AG, Computer Programs and Systems Inc, Merge Healthcare Inc, and Orchard Software Corporation. The regions covered in the laboratory information system market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the laboratory information system market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The global laboratory information system market is segmented - 1) By Product: Standalone LIS, Integrated LIS 2) By End User: Hospital Laboratories, Independent Laboratories, Physician Office Laboratories, Others 3) By Component: Software, Services

The 3D diagnostic imaging services market consists of revenues generated by the use of 3D diagnostic imaging procedures such as 3D X-rays, 3D ultrasound, MRI, and other 3D nuclear imaging techniques (PET, SPECT) to diagnose patients with chronic diseases. The 3D diagnostic imaging technique provides advanced services that help in various applications such as oncology, cardiology, orthopedics and others. 3D diagnostic imaging is used to create three dimensional visual representations of interior body parts for medical analysis with the help of computer-aided design (CAD) or a Magnetic Resonance Image (MRI) technology. The 3D diagnostic imaging services market covered in the report is segmented by technique into ultrasound, MRI, X-ray, computed tomography, others and by application into oncology, cardiology, orthopedics, others. The global 3D diagnostic imaging services market is expected grow from $172.25 billion in 2020 to $192.91 billion in 2021 at a compound annual growth rate (CAGR) of 12%. The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The 3D diagnostic imaging services market is expected to reach $255.4 billion in 2025 at a CAGR of 7%. The demand for point-of-care testing (PoCT) has been steadily increasing over the years. The growth in demand is likely to continue and drive the market for 3D diagnostic imaging services market. This is because PoCT allows physicians and medical staff to accurately achieve real-time, lab-quality diagnostic results within minutes rather than hours. Also, the changing healthcare delivery system is aimed at delivering cost effective care at patient’s home. In most of the countries, especially developing countries, more effective care for infectious diseases is needed. PoCT technologies provide effective care with easy-to-use devices and improved analytical performance and recent improvements in the speed, usability and affordability of medical imaging with 3D integration have greatly expanded the capabilities of PoCT testing systems. These advances are greatly driving the 3D diagnostic imaging services market. The 3D diagnostic imaging services market is constrained by the shortage of qualified and skilled healthcare resources. The main reasons are aging workforce, complexity of the latest procedures and their reluctance towards learning the new procedures, and shrinking number of accredited training programs. A report from the International Labor Organization estimates a global deficit of over 10.3 million skilled health professionals, and more than half of the deficit, totaling 7.1 million (69%), is in Asia. The shortage of skilled workforce is expected to affect the 3D diagnostic imaging services market. Therefore, there is an urgent need to train more healthcare professionals in the latest procedures and technologies including 3D imaging to enable accurate diagnosis and treatment in the most efficient manner. Introduction of improved data storage and information sharing systems such as medical cloud technology is creating more growth opportunities for 3D diagnostic imaging. This is because medical imaging requires adequate resources to process, store, exchange and use large quantities of medical data for appropriate diagnostic and treatment decisions, and advanced cloud computing in medical imaging addresses these concerns. Cloud computing is an emerging solution for questions related to delivering complex services and data interchange over the internet. Cloud computing technology enables medical data sharing across regions, allowing more patients to obtain the medical resources they need. It allows easy retrieval of data and provides doctors with more convenient clinical image data services (clear and informative images). Medical cloud imaging has become an important field of cloud computing. In January 2020, Metropolis Healthcare, a chain of diagnostic companies, acquired 51% stake in Shraddha Diagnostic Centre for Rs 9.36 Crores ($1.27 million). This acquisition helps Metropolis Healthcare expand its geographical reach in 9 cities and towns in India. Shraddha Diagnostics is a private company that majorly serves the B2B segment. Major players in the 3D diagnostic imaging services market are Laboratory Corporation of America Holdings, Quest Diagnostics Inc, Alere Inc., Bio-Reference Laboratories, DaVita Healthcare Partners Inc, Genomic Health Inc., Myriad Genetics Inc., NeoGenomics Inc., Sonic Healthcare Limited, and Spectra Laboratories. The regions covered in the 3D diagnostic imaging services market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the 3D diagnostic imaging services market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The global 3D diagnostic imaging services market is segmented - 1) By Technique: Ultrasound, MRI, X-ray, Computed Tomography, Others 2) By Application: Oncology, Cardiology, Orthopedic, Others 3) By End User: Diagnostic Centers, Hospitals, Research Centers

The healthcare reimbursement market consists of sales of healthcare reimbursement services by entities (organizations, sole traders and partnerships) that provide healthcare reimbursement services, which include the payment that hospitals, diagnostic facilities, doctors, or other health care providers receive for providing medical service to people. The healthcare reimbursement for a person's health care expenses is mostly covered partially or fully by the government or a health insurer. Only goods and services traded between entities or sold to end consumers are included. The healthcare reimbursement market covered in this report is segmented by claims into underpaid, full paid. The healthcare reimbursement market is also segmented by payers into private payers, public payers; by service provider into physician office, hospitals, diagnostic laboratories, others. The global healthcare reimbursement market is expected to decline from $15.19 billion in 2020 to $12.98 billion in 2021 at a compound annual growth rate (CAGR) of -14.5%. The decline is due to economic slowdown across countries owing to the COVID-19 outbreak and the measures to contain it. The healthcare reimbursement market is expected to reach $23.02 billion in 2025 at a CAGR of 15%. The increasing cost of healthcare and supportive government programs are the key factors that are driving the healthcare reimbursement market growth. According to the Journal of the American Medical Association (JAMA), US healthcare costs are expected to reach $6 trillion, which is $17,000 per person by 2027. In 2019, the US healthcare policy announced plans to expand healthcare insurance coverage and make changes to accountable care organizations. The rising healthcare cost and supportive government policies increase the number of people opting for payer services and thereby contributes to the growth of healthcare reimbursement market. Several incidences of fraud related to federal and state government health care programs hamper the growth of the healthcare reimbursement market. The medical insurance fraud and Medicare/Medicaid insurance fraud make up the majority of false claims in the USA. The National Health Care Anti-Fraud Association (NHCAA) reveals that unnecessary and duplicate tests and procedures, hacking into a patient’s medical records to submit false claims, billing services never rendered, falsifying diagnosis are some common situations that occur. According to the Department of Justice, one of the largest health care fraud enforcement actions across seven federal districts in the Northeastern United States, involved more than $800 million in loss and the distribution of over 3.25 million pills of opioids in "pill mill" clinics. The rise in healthcare fraud related to federal and state government programs create huge loss for the business restraining the growth of the healthcare reimbursement market. Companies in the healthcare reimbursement market are providing options of value-based care models to cater better experience for the patients. Value-based care models are based on the quality of patient's treatment and how well healthcare providers can improve their quality by adhering to certain metrics such as reducing hospital readmissions, improving preventative care, and using particular kinds of certified health technology and help lower healthcare costs. For instance, UnitedHealth estimated that its payments to healthcare providers based on value-based care relationships will be $75 billion by 2020. In March 2019, Centern Corporation, a large publicly-traded company and a multi-line managed care enterprise, acquired WellCare for $17.3 billion. The transaction will result in the establishment of a premier organization providing government-sponsored healthcare programs along with having expertise in Medicaid, Medicare, and Health insurance marketplace. WellCare Health Plans, Inc. is an American health insurance company that provides managed care services primarily through Medicaid, Medicare Advantage, and Medicare prescription drug plans for more than 6.3 million members across the country. Major players in the healthcare reimbursement market are UnitedHealth Group, Aviva, Allianz, CVS Health, BNP Paribas, Aetna, Nippon Life Insurance, WellCare Health Plans, AgileHealthInsurance, and Blue Cross Blue Shield Association. The regions covered in the healthcare reimbursement market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the healthcare reimbursement market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The global healthcare reimbursement market is segmented - 1) By Claims: Underpaid, Full Paid 2) By Payers: Private Payers, Public Payers 3) By Service Provider: Physician Office, Hospitals, Diagnostic Laboratories, Others

The synthetic biology market consists of sales of synthetic compound, technology and related services. Synthetic biology is a field of biology science which involve engineering principles. The synthetic biology market covered in this report is segmented by technology into nucleotide synthesis and sequencing, bioinformatics, microfluidics, genetic engineering. The synthetic biology market is also segmented by application into pharmaceuticals and diagnostics, chemicals, biofuels, bioplastics, others and by product type into oligonucleotides, enzymes, cloning and assembly kits, xeno-nucleic acids (XNA), chassis organism. The global synthetic biology market is expected to grow from $8.64 billion in 2020 to $10.07 billion in 2021 at a compound annual growth rate (CAGR) of 16.6%. The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The synthetic biology market is expected to reach $28.91 billion in 2025 at a CAGR of 30.2%. DNA sequencing is important in development of the synthetic biology in many ways. The DNA sequencing finds its use in many synthetic biology applications, therefore the availability of the DNA sequencing technique at low cost drives the production of products based on the applications of synthetic biology. DNA sequencing allows the researchers to determine the DNA sequences in genes and helps a researcher to create a repository of entire genomes. These repositories form the basis for the implementation of synthetic biology applications such as protein expression, directed evolution, and metabolic engineering. According to the World Economic Forum report in 2019, costs per genome sequenced have been decreased from $3 billion to less than $1,000 over the past 15 years and are projected to be gradually lowered by 10 times over the next five years. The bio-safety risks involved in synthetic biology restrains the synthetic biology market. Synthetic biology involves researches on micro-organism to perform the desired function or produce a biological desired substance. Such processes possess health risks such as illness, allergies in humans as well as environmental risks such as toxicity and risk of new micro-organisms affecting living creatures in the ecosystem. Such potential risks pose as a deterrent to possible innovative research that could be done in certain fields such as combating epidemics such as Ebola and life-threatening diseases such as cancer. The new technological advances in the field of DNA sequencing has enabled the researchers to use DNA to store non-genetic information. With the rise in the demand to store quantum of data, DNA data storage offers a solution where one DNA strand can store about 455 Exabyte of data (455 billion gigabytes). Thus, the concept has received huge investments from the entities in the market. The binary data (data coded in 0O and 1) is converted into DNA strings of four potential base units of unique sequences of A, G, C, T (DNA is made up of four base components: Adenine, Guanine, Cytosine, and Thymine (known as AGCT)). The information coded in DNA lasts for thousands of years when compared to the data in traditional hard drives which gets corrupted or damaged within 30 years. For instance, according to a journal published by Nature Publishing Group, Microsoft and University of Washington researchers stored 35 distinct digital files in DNA—more than 200 megabytes of data and plans to increase future investment to improve the technology. In March 2020, Zymergen, a California based material innovation company rethinking biology and reimagining the world acquired enEvolv, Inc. for an undisclosed amount. This acquisition speeds Zymergen delivery of high performance and sustainable products to customers and further cements Zymergen leadership position in the bio-manufacturing space. enEvolv, Inc, a next-generation synthetic biology company that has developed an enzyme and strain development platform to harness the power of evolution and create unique, commercial products by engineering the genomes of microbes. Major players in the synthetic biology market are Thermo Fischer Scientific, Genscript, Integrated DNA Technologies, Amyris and Twist Bioscience Corporation. The regions covered in the synthetic biology market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the synthetic biology market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The global synthetic biology market is segmented - 1) By Technology: Nucleotide Synthesis And Sequencing, Bioinformatics, Microfluidics, Genetic Engineering 2) By Application: Pharmaceuticals And Diagnostics, Chemicals, Biofuels, Bioplastics, Others 3) By Product Type: Oligonucleotides, Enzymes, Cloning And Assembly Kits, Xeno-Nucleic Acids (XNA), Chassis Organism

The metabolic disorders drugs market consists of sales of metabolic disorders drugs and related services by entities (organizations, sole traders and partnerships) that produce metabolic disorders drugs to treat metabolic diseases. This industry includes establishments that produce drugs such as insulin, pramlintide and other drugs to treat diabetes, anti-thyroid drugs to treat hyperthyroidism, and other drugs to treat pituitary gland, adrenal gland and parathyroid gland disorders. The metabolic disorders drugs market is segmented into anti diabetic drugs; anti-thyroid drugs; and others (hyperparathyroidism, hypopituitarism, hypoadrenalism). The global metabolic disorders drugs market is expected to grow from $143.16 billion in 2020 to $146.25 billion in 2021 at a compound annual growth rate (CAGR) of 2.2%. The growth is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $198.07 billion in 2025 at a CAGR of 8%. North America was the largest region in the global metabolic disorders drugs market, accounting for 54% of the market in 2020. Asia Pacific was the second largest region, accounting for 24% of the global metabolic disorders drugs market. Africa was the smallest region in the global metabolic disorders drugs market. The rise in sedentary jobs, busy lifestyles and changing consumer preferences are affecting the disease profile of the world population, especially non-communicable diseases such as diabetes and obesity. Long working hours, less physical activity, and unhealthy eating and drinking habits are major causes of metabolic disorders. According to the World Health Organization, chronic disease prevalence is expected to rise by 57% globally, by the year 2020. These factors are expected to increase the patient pool globally, thereby driving the metabolic disorders drugs market during the forecast period. Regulatory agencies and federal governments adopted stringent regulations and took a tough stance on drug pricing by pharmaceutical companies during the historic period. Pharmaceutical companies faced criticism from politicians, patients and physicians over high pricing of some medicines and drugs. Moreover, companies had to sell drugs and medicines at subsidized rates to government hospitals, doctors and clinics, further effecting companies’ revenues. This led to drug manufacturing companies operating on a reduced profit margin, which negatively impacted the attractiveness of the metabolic disorders drugs industry in the historic period. Companies are focusing on employing artificial intelligence applications to revolutionize the treatment of metabolic disorders. Artificial Intelligence is a machine-based learning which makes use of human intelligence functionalities like reasoning and problem-solving abilities to obtain insights and provide useful information. This technology radically changes the treatment of metabolic syndrome by analyzing large sets of chemical and biological data to identify potential drug candidates with higher success rates and at a quicker pace when compared to human analysis. 3BIGS, a Korean biodata analysis-based company that studies the relation between diseases, targets and drugs is using AI technology to help researches repurpose the drugs for additional diseases. The major players covered in the global metabolic disorders drugs market are Sanofi S.A, Novo Nordisk A/S, AstraZeneca Plc, Johnson & Johnson, Merck & Co. The countries covered in the global metabolic disorders drugs market are Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, Czech Republic, Denmark, Egypt, Finland, France, Germany, Hong Kong, India, Indonesia, Ireland, Israel, Italy, Japan, Malaysia, Mexico, Netherlands, New Zealand, Nigeria, Norway, Peru, Philippines, Poland, Portugal, Romania, Russia, Saudi Arabia, Singapore, South Africa, South Korea, Spain, Sweden, Switzerland, Thailand, Turkey, UAE, UK, USA, Venezuela, Vietnam. The regions covered in the global metabolic disorders drugs market are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The global metabolic disorders drugs market is segmented - 1) By Type: Anti Diabetics drugs, Anti-Thyroid Drugs, Others (Hyperparathyroidism, Hypopituitarism, Hypoadrenalism) 2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies/ Drug Stores, Others 3) By Route Of Administration: Oral, Parenteral, Others 4) By Drug Classification: Branded Drugs, Generic Drugs 5) By Mode Of Purchase: Prescription-Based Drugs, Over-The-Counter Drugs